PRECISION BIOSCIENCES INC (DTIL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '21: 118M Q4 '21: 115.5M Q1 '22: 102.5M Q2 '22: 37.5M Q3 '22: 20.8M Q4 '22: 25.1M Q1 '23: 30.6M Q2 '23: 46.5M Q3 '23: 52.3M Q4 '23: 48.7M Q1 '24: 57.5M Q2 '24: 87.6M Q3 '24: 75.1M Q4 '24: 68.7M Q1 '25: 51.1M Q2 '25: 1.3M Q3 '25: 698K Q4 '25: 34.3M Q1 '26: 45.1M Q2 '26: 45.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -32.1M Q4 '21: -39.4M Q1 '22: -48M Q2 '22: -99.2M Q3 '22: -102.3M Q4 '22: -83.7M Q1 '23: -69.7M Q2 '23: -43.3M Q3 '23: -41M Q4 '23: -43.7M Q1 '24: -34.6M Q2 '24: -7.3M Q3 '24: -16.2M Q4 '24: -26.2M Q1 '25: -44.1M Q2 '25: -90.1M Q3 '25: -89.5M Q4 '25: -52.1M Q1 '26: -39.1M Q2 '26: -36.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -31.8M Q4 '21: -30.6M Q1 '22: -40.1M Q2 '22: -92.8M Q3 '22: -105.4M Q4 '22: -111.6M Q1 '23: -108.5M Q2 '23: -89.4M Q3 '23: -73.5M Q4 '23: -61.3M Q1 '24: -27.7M Q2 '24: 17M Q3 '24: 8.6M Q4 '24: 7.2M Q1 '25: -22M Q2 '25: -78.3M Q3 '25: -83.6M Q4 '25: -45.7M Q1 '26: -43.6M Q2 '26: -52.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -624K Q4 '21: -10.9M Q1 '22: -107.8M Q2 '22: -100.7M Q3 '22: -47.6M Q4 '22: -45.8M Q1 '23: -48.3M Q2 '23: -45.3M Q3 '23: -97.5M Q4 '23: -84.1M Q1 '24: -71.6M Q2 '24: -65.4M Q3 '24: -48.2M Q4 '24: -58.4M Q1 '25: -58.5M Q2 '25: -63.9M Q3 '25: -73.3M Q4 '25: -65.8M Q1 '26: -58.7M Q2 '26: -51.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -5.3M Q4 '21: -15.9M Q1 '22: -112.5M Q2 '22: -104.5M Q3 '22: -51.8M Q4 '22: -49.1M Q1 '23: -51.4M Q2 '23: -48.6M Q3 '23: -100.1M Q4 '23: -86.1M Q1 '24: -73.2M Q2 '24: -65.8M Q3 '24: -48.3M Q4 '24: -58.7M Q1 '25: -58.7M Q2 '25: -64.1M Q3 '25: -73.4M Q4 '25: -65.9M Q1 '26: -58.8M Q2 '26: -51.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '20: 51.9M Q2 '21: 59.8M Q3 '21: 59.7M Q1 '22: 61M Q2 '22: 68M Q3 '22: 110.8M Q1 '23: 3.7M Q2 '23: 3.8M Q3 '23: 3.8M Q1 '24: 5.1M Q2 '24: 7M Q3 '24: 7.3M Q1 '25: 9.3M Q2 '25: 11M Q3 '25: 11.8M Q1 '26: 24.6M Q2 '26: 25.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '21: -0.60 Q4 '21: -0.54 Q1 '22: -0.67 Q2 '22: -1.49 Q3 '22: -1.52 Q4 '22: -38.20 Q1 '23: -44.49 Q2 '23: -47.16 Q3 '23: -49.04 Q4 '23: -16.04 Q1 '24: -7.59 Q2 '24: 0.21 Q3 '24: 0.06 Q4 '24: 1.04 Q1 '25: -2.87 Q2 '25: -9.67 Q3 '25: -9.26 Q4 '25: -3.56 Q1 '26: -2.10 Q2 '26: -1.23 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.